Apremilast is the only approved oral PDE4 inhibitor by the U.S. Food and Drug Administration (FDA) for psoriasis treatment and is helping to fill an important treatment gap in psoriasis (18, 19). This evidence concerns the gene PDE4A and psoriasis.